CYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES

This study was carried out to determine the metabolic pathways of buspirone and cytochrome P450 (P450) isoform(s) responsible for buspirone metabolism in human liver microsomes (HLMs). Buspirone mainly underwent N-dealkylation to 1-pyrimidinylpiperazine (1-PP), N-oxidation on the piperazine ring to buspirone N-oxide (Bu N-oxide), and hydroxylation to 3′-hydroxybuspirone (3′-OH-Bu), 5-hydroxybuspirone (5-OH-Bu), and 6′-hydroxybuspirone (6′-OH-Bu) in HLMs. The apparent Km values for buspirone metabolite formation in pooled HLMs were 8.7 (1-PP), 34.0 (Bu N-oxide), 4.3 (3′-OH-Bu), 11.4/514 (5-OH-Bu), and 8.8 μM (6′-OH-Bu). CYP3A inhibitor ketoconazole (1 μM) completely inhibited the formation of all major metabolites in HLMs (0-16% of control), whereas the chemical inhibitor selective to other P450 isoforms had little or no inhibitory effect. Recombinant CYP3A4, CYP3A5, and CYP2D6 exhibited buspirone oxidation activities among nine P450 isoforms tested. The overall metabolism rate of 5 μM buspirone by CYP3A4 was 18-fold greater than that by CYP2D6 and 35-fold greater than that by CYP3A5. In a panel of HLMs from 16 donors, buspirone metabolism correlated well CYP3A activity (r2 = 0.85-0.96, ρ < 0.0005), but not the activities of other P450 isoforms. The metabolism rates of buspirone in CYP2D6 poor-metabolizer genotype HLMs were comparable to those in pooled HLMs. Taken together, these data suggest that CYP3A, mostly likely CYP3A4, is primarily responsible for the metabolism of buspirone in HLMs.

[1]  I. Blair,et al.  In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  J. O'Hanlon.  Review of buspirone's effects on human performance and related variables , 1991, European Neuropsychopharmacology.

[3]  P. Neuvonen,et al.  Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole , 1997, Clinical pharmacology and therapeutics.

[4]  R. Mayol,et al.  The relationship between buspirone bioavailability and dose in healthy subjects. , 1985, Biopharmaceutics & drug disposition.

[5]  P. Neuvonen,et al.  Grapefruit juice substantially increases plasma concentrations of buspirone , 1998, Clinical pharmacology and therapeutics.

[6]  R. Mayol,et al.  Metabolism and disposition of buspirone. , 1986, The American journal of medicine.

[7]  W. Trager,et al.  (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[8]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[9]  I. Mahmood,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug , 1999, Clinical pharmacokinetics.

[10]  Shiew-Mei Huang,et al.  Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential‐toward a consensus , 2001 .

[11]  S. Garattini,et al.  Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. , 1983, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  L. Fabre,et al.  Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects , 1998, Psychopharmacology.

[13]  P. Neuvonen,et al.  Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. , 1999, Pharmacology & toxicology.

[14]  P. Neuvonen,et al.  Concentrations and effects of buspirone are considerably reduced by rifampicin. , 1998, British journal of clinical pharmacology.

[15]  N. Cutler,et al.  Generalised anxiety disorder: treatment options. , 2002, Drugs.

[16]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[17]  I. Blair,et al.  Metabolism of the antianxiety drug buspirone in human subjects. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[18]  K. Goa,et al.  Buspirone , 2020, Drugs.

[19]  R. Huupponen,et al.  Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone , 2003, European Journal of Clinical Pharmacology.

[20]  J B Houston,et al.  Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. , 2001, British journal of clinical pharmacology.

[21]  R. N. Brogden,et al.  Buspirone: An Updated Review of its Clinical Pharmacology and Therapeutic Applications , 1997 .

[22]  I. Blair,et al.  Metabolism of the antianxiety drug buspirone in the rat. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[23]  I. Blair,et al.  Liquid chromatography/chemical reaction interface mass spectrometry as an alternative to radioisotopes for quantitative drug metabolism studies. , 1996, Analytical chemistry.

[24]  J. Apter,et al.  Buspirone: future directions. , 1999, Journal of clinical psychopharmacology.

[25]  P. Neuvonen,et al.  Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone , 1998, Clinical pharmacology and therapeutics.

[26]  R. Rourick,et al.  Buspirone metabolite structure profile using a standard liquid chromatographic-mass spectrometric protocol. , 1997, Journal of chromatography. B, Biomedical sciences and applications.